25769-61-3 Usage
Description
Glycolic Anhydride Diacetate is a chemical compound that is produced through a reaction involving Lead tetraacetate as an oxidizing agent. It serves as an intermediate in the synthesis of Chrysogine, a metabolite of Penicillium chrysogenum, and some related 2-substituted 4-(3H)-quinazolinones.
Uses
Used in Pharmaceutical Industry:
Glycolic Anhydride Diacetate is used as an intermediate for the synthesis of various pharmaceutical compounds, including Chrysogine and other related 2-substituted 4-(3H)-quinazolinones. Its role in the synthesis process is crucial for the development of these compounds, which may have potential applications in the treatment of various medical conditions.
Used in Chemical Synthesis:
Glycolic Anhydride Diacetate is also used as a chemical intermediate in the synthesis of other organic compounds. Its unique structure and reactivity make it a valuable building block for creating a wide range of chemical products, contributing to the advancement of various industries that rely on chemical synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 25769-61-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,7,6 and 9 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 25769-61:
(7*2)+(6*5)+(5*7)+(4*6)+(3*9)+(2*6)+(1*1)=143
143 % 10 = 3
So 25769-61-3 is a valid CAS Registry Number.
25769-61-3Relevant articles and documents
Pyridylmethylthio derivatives as VEGF inhibitors: Part 2
Tajima, Hisashi,Honda, Takahiro,Kawashima, Kenji,Sasabuchi, Yoshimasa,Yamamoto, Minoru,Ban, Masakazu,Okamoto, Kazuyoshi,Inoue, Kenji,Inaba, Takaaki,Takeno, Yuriko,Tsuboi, Takashi,Tonouchi, Asaka,Aono, Hiroyuki
supporting information; experimental part, p. 1232 - 1235 (2011/04/16)
Optimization of compounds 5 and 6 led to the discovery of VEGF inhibitor 10g which reduced CYP inhibition. It was highly active in vitro (VEGF induced HUVEC proliferation assay) and showed efficacies in three disease models in vivo (cancer, RA, and AMD).
